X

Trial Profile

A Phase I, Multicenter, Open-label, Dose Escalation Study of Intratumoral Injections of VCN-01 Oncolytic Adenovirus With Intravenous Gemcitabine and Abraxane in Advanced Pancreatic Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Jan 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VCN 01 (Primary) ; Gemcitabine; Paclitaxel
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions; Proof of concept
Sponsors Theriva Biologics; VCN Biosciences

Most Recent Events

03 Sep 2019 According to a VCN Bioscience media release, data from this trial will be presented at the annual meeting of the European Society of Medical Oncology (ESMO) in Barcelona, 27 September -1 October 2019.
27 Sep 2018 Status changed from active, no longer recruiting to completed.
02 May 2018 Planned End Date changed from 1 Apr 2018 to 1 Sep 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com